Agile Therapeutics (NASDAQ:AGRX – Get Free Report) and ProPhase Labs (NASDAQ:PRPH – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.
Volatility and Risk
Agile Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Agile Therapeutics and ProPhase Labs, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agile Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
| ProPhase Labs | 0 | 0 | 1 | 0 | 3.00 |
Profitability
This table compares Agile Therapeutics and ProPhase Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agile Therapeutics | -73.83% | N/A | -179.07% |
| ProPhase Labs | -37.81% | -29.83% | -18.14% |
Institutional & Insider Ownership
10.9% of Agile Therapeutics shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 0.5% of Agile Therapeutics shares are owned by company insiders. Comparatively, 26.1% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Agile Therapeutics and ProPhase Labs’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agile Therapeutics | $19.59 million | 0.15 | -$14.47 million | ($9.84) | -0.04 |
| ProPhase Labs | $44.38 million | 2.19 | -$16.78 million | ($0.98) | -5.50 |
Agile Therapeutics has higher earnings, but lower revenue than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
ProPhase Labs beats Agile Therapeutics on 7 of the 13 factors compared between the two stocks.
About Agile Therapeutics
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It also offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
